|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A6, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Graff RE, Meisner A, Ahearn TU, Fiorentino
M, Loda M, Giovannucci EL, Mucci LA and Pettersson A:
Pre-diagnostic circulating sex hormone levels and risk of prostate
cancer by ERG tumour protein expression. Br J Cancer. 114:939–944.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cornford P, Bellmunt J, Bolla M, Briers E,
De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, et al:
EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of
relapsing, metastatic and castration-resistant prostate cancer. Eur
Urol. 71:630–642. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
James ND, de Bono JS, Spears MR, Clarke
NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones
RJ, et al: Abiraterone for prostate cancer not previously treated
with hormone therapy. N Engl J Med. 377:338–351. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sweeney CJ, Chen YH, Carducci M, Liu G,
Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et
al: Chemohormonal therapy in metastatic hormone-sensitive prostate
cancer. N Engl J Med. 373:737–746. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sammon JD, Abdollah F, Reznor G, Pucheril
D, Choueiri TK, Hu JC, Kim SP, Schmid M, Sood A, Sun M, et al:
Patterns of declining use and the adverse effect of primary
androgen deprivation on all-cause mortality in elderly men with
prostate cancer. Eur Urol. 68:32–39. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Armitage JO and Sidner RD: Antitumour
effect of cimetidine. Lancet. 1:882–883. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang WT, Chen YH, Hsu JL, Leu WJ, Yu CC,
Chan SH, Ho YF, Hsu LC and Guh JH: Terfenadine induces
anti-proliferative and apoptotic activities in human
hormone-refractory prostate cancer through histamine
receptor-independent Mcl-1 cleavage and Bak up-regulation. Naunyn
Schmiedebergs Arch Pharmacol. 387:33–45. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blaya B, Nicolau-Galmés F, Jangi SM,
Ortega-Martínez I, Alonso-Tejerina E, Burgos-Bretones J,
Pérez-Yarza G, Asumendi A and Boyano MD: Histamine and histamine
receptor antagonists in cancer biology. Inflamm Allergy Drug
Targets. 9:146–157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng Y, Xu M, Li X, Jia J, Fan K and Lai
G: Cimetidine suppresses lung tumor growth in mice through
proapoptosis of myeloid-derived suppressor cells. Mol Immunol.
54:74–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tanaka S, Sakaguchi M, Yoneyama H, Usami Y
and Harusawa S: Histamine H3 receptor antagonist OUP-186 attenuates
the proliferation of cultured human breast cancer cell lines.
Biochem Biophys Res Commun. 480:479–485. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin JJ, Zhao TZ, Cai WK, Yang YX, Sun C,
Zhang Z, Xu YQ, Chang T and Li ZY: Inhibition of histamine receptor
3 suppresses glioblastoma tumor growth, invasion, and
epithelial-to-mesenchymal transition. Oncotarget. 6:17107–17120.
2015.PubMed/NCBI
|
|
14
|
Donoso AO and Banzan AM: H1- and
H2-histamine receptor antagonists and induced release of prolactin
in male rats. Neuroendocrinology. 30:11–14. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin Y, Fukuchi J, Hiipakka RA, Kokontis JM
and Xiang J: Up-regulation of Bcl-2 is required for the progression
of prostate cancer cells from an androgen-dependent to an
androgen-independent growth stage. Cell Res. 17:531–536. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu C, Lou W, Armstrong C, Zhu Y, Evans CP
and Gao AC: Niclosamide suppresses cell migration and invasion in
enzalutamide resistant prostate cancer cells via Stat3-AR axis
inhibition. Prostate. 75:1341–1353. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Barber AG, Castillo-Martin M, Bonal DM,
Jia AJ, Rybicki BA, Christiano AM and Cordon-Cardo C: PI3K/AKT
pathway regulates E-cadherin and Desmoglein 2 in aggressive
prostate cancer. Cancer Med. 4:1258–1271. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Koh CM, Bieberich CJ, Dang CV, Nelson WG,
Yegnasubramanian S and De Marzo AM: MYC and prostate cancer. Genes
Cancer. 1:617–628. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gray IC, Stewart LM, Phillips SM, Hamilton
JA, Gray NE, Watson GJ, Spurr NK and Snary D: Mutation and
expression analysis of the putative prostate tumour-suppressor gene
PTEN. Br J Cancer. 78:1296–1300. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Green AJ, Gelfand JM, Cree BA, Bevan C,
Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, et
al: Clemastine fumarate as a remyelinating therapy for multiple
sclerosis (ReBUILD): A randomised, controlled, double-blind,
crossover trial. Lancet. 390:2481–2489. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rossing MA, Scholes D, Cushing-Haugen KL
and Voigt LF: Cimetidine use and risk of prostate and breast
cancer. Cancer Epidemiol Biomarkers Prev. 9:319–323.
2000.PubMed/NCBI
|
|
23
|
Ragnarsson O, Johannsson G, Geterud K,
Lodding P and Dahlqvist P: Inadequate testosterone suppression
after medical and subsequent surgical castration in a patient with
prostate cancer. BMJ Case Rep. 2013:pii: bcr20130103952013.
View Article : Google Scholar
|
|
24
|
Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J,
Chen Z, Beroukhim R, Wang H, Lupien M, et al: Androgen receptor
regulates a distinct transcription program in androgen-independent
prostate cancer. Cell. 138:245–256. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yeap BB, Krueger RG and Leedman PJ:
Differential posttranscriptional regulation of androgen receptor
gene expression by androgen in prostate and breast cancer cells.
Endocrinology. 140:3282–3291. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu X, Ledet E, Li D, Dotiwala A,
Steinberger A, Feibus A, Li J, Qi Y, Silberstein J, Lee B, et al: A
whole blood assay for AR-V7 and ARv567es in patients with prostate
cancer. J Urol. 196:1758–1763. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu Z, Chen S, Sowalsky AG, Voznesensky OS,
Mostaghel EA, Nelson PS, Cai C and Balk SP: Rapid induction of
androgen receptor splice variants by androgen deprivation in
prostate cancer. Clin Cancer Res. 20:1590–1600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sharma NL, Massie CE, Ramos-Montoya A,
Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY,
Mills IG and Neal DE: The androgen receptor induces a distinct
transcriptional program in castration-resistant prostate cancer in
man. Cancer Cell. 23:35–47. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mills IG: Maintaining and reprogramming
genomic androgen receptor activity in prostate cancer. Nat Rev
Cancer. 14:187–198. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li Z, Alyamani M, Li J, Rogacki K, Abazeed
M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ and Sharifi N:
Redirecting abiraterone metabolism to fine-tune prostate cancer
anti-androgen therapy. Nature. 533:547–551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pfanzagl B, Mechtcheriakova D,
Meshcheryakova A, Aberle SW, Pfragner R and Jensen-Jarolim E:
Activation of the ileal neuroendocrine tumor cell line P-STS by
acetylcholine is amplified by histamine: Role of H3R and H4R. Sci
Rep. 7:13132017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Davenas E, Rouleau A, Morisset S and
Arrang JM: Autoregulation of McA-RH7777 hepatoma cell proliferation
by histamine H3 receptors. J Pharmacol Exp Ther. 326:406–413. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Medina V, Croci M, Crescenti E, Mohamad N,
Sanchez-Jiménez F, Massari N, Nuñez M, Cricco G, Martin G, Bergoc R
and Rivera E: The role of histamine in human mammary
carcinogenesis: H3 and H4 receptors as potential therapeutic
targets for breast cancer treatment. Cancer Biol Ther. 7:28–35.
2008. View Article : Google Scholar : PubMed/NCBI
|
